Search Results - "Haspinger, Eva"

Limits of radiomic-based entropy as a surrogate of tumor heterogeneity: ROI-area, acquisition protocol and tissue site exert substantial influence by Dercle, Laurent, Ammari, Samy, Bateson, Mathilde, Durand, Paul Blanc, Haspinger, Eva, Massard, Christophe, Jaudet, Cyril, Varga, Andrea, Deutsch, Eric, Soria, Jean-Charles, Ferté, Charles

“…Entropy is a promising quantitative imaging biomarker for characterizing cancer imaging phenotype. Entropy has been associated with tumor gene expression,…”
Get full text

Design and development of a peptide-based adiponectin receptor agonist for cancer treatment by Otvos, Jr, Laszlo, Haspinger, Eva, La Russa, Francesca, Maspero, Federica, Graziano, Patrizia, Kovalszky, Ilona, Lovas, Sandor, Nama, Kaushik, Hoffmann, Ralf, Knappe, Daniel, Cassone, Marco, Wade, John, Surmacz, Eva

“…Adiponectin, a fat tissue-derived adipokine, exhibits beneficial effects against insulin resistance, cardiovascular disease, inflammatory conditions, and…”
Get full text

Epidermal growth factor receptor tyrosine kinase inhibitor treatment in patients with EGFR wild-type non-small-cell lung cancer: the never-ending story by Gelsomino, Francesco, Agustoni, Francesco, Niger, Monica, Valota, Marika, Haspinger, Eva R

Get full text

Infection rate and clinical management of cancer patients during the COVID-19 pandemic: experience from a tertiary care hospital in northern Italy by Fong, Dominic, Rauch, Simon, Petter, Christian, Haspinger, Eva, Alber, Monika, Mitterer, Manfred

“…BackgroundOptimal management of patients with cancer during COVID-19 pandemic is still pending.MethodsOur patients were advised to maintain their scheduled…”
Get full text

Do we really need another epidermal growth factor receptor tyrosine kinase inhibitor in first-line treatment for patients with non-small-cell lung cancer and EGFR mutations? by Haspinger, Eva R, Garassino, Marina Chiara, Torri, Valter, Cinquini, Michela, De Braud, Filippo, Gelsomino, Francesco

Get full text

Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer by Fabi, Alessandra, Carbognin, Luisa, Botticelli, Andrea, Paris, Ida, Fuso, Paola, Savastano, Maria Cristina, La Verde, Nicla, Strina, Carla, Pedersini, Rebecca, Guarino, Stefania, Curigliano, Giuseppe, Criscitiello, Carmen, Raffaele, Mimma, Beano, Alessandra, Franco, Antonio, Valerio, Maria Rosaria, Verderame, Francesco, Fontana, Andrea, Haspinger, Eva Regina, Caldara, Alessia, Di Leone, Alba, Tortora, Giampaolo, Giannarelli, Diana, Scambia, Giovanni

Get full text

Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer by Fabi, Alessandra, Carbognin, Luisa, Botticelli, Andrea, Paris, Ida, Fuso, Paola, Savastano, Maria Cristina, La Verde, Nicla, Strina, Carla, Pedersini, Rebecca, Guarino, Stefania, Curigliano, Giuseppe, Criscitiello, Carmen, Raffaele, Mimma, Beano, Alessandra, Franco, Antonio, Valerio, Maria Rosaria, Verderame, Francesco, Fontana, Andrea, Haspinger, Eva Regina, Caldara, Alessia, Di Leone, Alba, Tortora, Giampaolo, Giannarelli, Diana, Scambia, Giovanni

“…The combination of atezolizumab and nab-paclitaxel is recommended in the EU as first-line treatment for PD-L1-positive metastatic triple-negative breast cancer…”
Get full text

Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer by Fabi, Alessandra, Carbognin, Luisa, Botticelli, Andrea, Paris, Ida, Fuso, Paolo, Savastano, Maria Cristina, La Verde, Nicla, Strina, Carla, Pedersini, Rebecca, Guarino, Stefania, Curigliano, Giuseppe, Criscitiello, Carmen, Raffaele, Mimma, Beano, Alessandra, Franco, Antonio, Valerio, Maria Rosaria, Verderame, Francesco, Fontana, Andrea, Haspinger, Eva Regina, Caldara, Alessia, Di Leone, Alba, Tortora, Giampaolo, Giannarelli, Diana, Scambia, Giovanni

Get full text

Does Immunohistochemistry Affect Response to Therapy and Survival of Inoperable Non–Small Cell Lung Carcinoma Patients? A Survey of 145 Stage III-IV Consecutive Cases by Pelosi, Giuseppe, Haspinger, Eva Regina, Bimbatti, Manuela, Leone, Giorgia, Paolini, Biagio, Fabbri, Alessandra, Tamborini, Elena, Perrone, Federica, Testi, Adele, Garassino, Marina, Maisonneuve, Patrick, de Braud, Filippo, Pilotti, Silvana, Pastorino, Ugo

“…Whether non–small cell lung carcinoma (NSCLC) unveiled by immunohistochemistry (IHC) has the same clinical outcome as those typed by morphology is still matter…”
Get full text

Is there evidence for different effects among EGFR-TKIs? Systematic review and meta-analysis of EGFR tyrosine kinase inhibitors (TKIs) versus chemotherapy as first-line treatment for patients harboring EGFR mutations by Haspinger, Eva Regina, Agustoni, Francesco, Torri, Valter, Gelsomino, Francesco, Platania, Marco, Zilembo, Nicoletta, Gallucci, Rosaria, Garassino, Marina Chiara, Cinquini, Michela

“…Highlights • Comparison between chemotherapy and TKIs in patients with NSCLC EGFR-positive • Systematic review and meta-analysis to estimate the risk/benefit…”
Get full text

Optimizing CDK4/6 inhibitors in advanced HR+/HER2- breast cancer: A personalized approach by Fontanella, Caterina, Giorgi, Carlo Alberto, Russo, Stefania, Angelini, Silvia, Nicolardi, Linda, Giarratano, Tommaso, Frezzini, Simona, Pestrin, Marta, Palleschi, Dario, Bolzonello, Silvia, Parolin, Veronica, Haspinger, Eva R., De Rossi, Costanza, Greco, Filippo, Gerratana, Lorenzo

“…Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) combined with endocrine therapy (ET) are now a backbone of treatment for hormone receptor-positive/human…”
Get full text

Emerging toxicities in the treatment of non-small cell lung cancer: Ocular disorders by Agustoni, Francesco, Platania, Marco, Vitali, Milena, Zilembo, Nicoletta, Haspinger, Eva, Sinno, Valentina, Gallucci, Rosaria, de Braud, Filippo, Garassino, Marina Chiara

“…Abstract The treatment of advanced disease (stage IIIb and IV) of non-small cell lung cancer (NSCLC) is based on systemic treatment with platinum-based…”
Get full text

Metformin inhibits leptin-induced growth and migration of glioblastoma cells by FERLA, RITA, HASPINGER, EVA, SURMACZ, EVA

“…Metformin, a derivative of biguanide, is a first-line therapy for type 2 diabetes mellitus. Since the drug has been shown to significantly reduce the risk of…”
Get full text

Prognostic value of histogram analysis in advanced non-small cell lung cancer: a radiomic study by Virginia, Bluthgen Maria, Laura, Faivre, Silvia, Rosellini, Roberto, Ferrara, Francesco, Facchinetti, Eva, Haspinger, Charles, Ferte, Samy, Ammari, Stefan, Michiels, Jean-Charles, Soria, Caroline, Caramella, Benjamin, Besse

“…Quantitative assessment of heterogeneity by histogram analysis (HA) of tumor images can potentially provide a non-invasive prognostic biomarker. We assessed…”
Get full text

Activity of the EGFR-HER2 Dual Inhibitor Afatinib in EGFR-Mutant Lung Cancer Patients With Acquired Resistance to Reversible EGFR Tyrosine Kinase Inhibitors by Landi, Lorenza, Tiseo, Marcello, Chiari, Rita, Ricciardi, Serena, Rossi, Elisa, Galetta, Domenico, Novello, Silvia, Milella, Michele, D'Incecco, Armida, Minuti, Gabriele, Tibaldi, Carmelo, Salvini, Jessica, Facchinetti, Francesco, Haspinger, Eva Regina, Cortinovis, Diego, Santo, Antonio, Banna, Giuseppe, Catino, Annamaria, GiajLevra, Matteo, Crinò, Lucio, de Marinis, Filippo, Cappuzzo, Federico

“…Micro-Abstract In this retrospective study we evaluated the outcome of 96 epidermal growth factor receptor (EGFR)-mutant non–small-cell lung cancer (NSCLC)…”
Get full text

Fatal case of hepatic portal venous gas following palliative stenting and chemotherapy for occlusive advanced colorectal cancer by Platania, Marco, Valeri, Barbara, Marchianò, Alfonso, Calareso, Giuseppina, Agustoni, Francesco, Haspinger, Eva, Pusceddu, Sara, Garassino, Marina Chiara, Gelsomino, Francesco, de Braud, Filippo

Get full text